Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 18/20 | 0.63 |
| ▸ | F10 | P00742 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20584748 | 0.91 | KLKB1 (0.60) | KLKB1F10 | |
| SCHEMBL20584704 | 0.87 | KLKB1 (0.48) | KLKB1 | |
| SCHEMBL20584370 | 0.83 | KLKB1 (0.63) | KLKB1F10 | |
| SCHEMBL31456809 | 0.83 | KLKB1 (0.63) | KLKB1F10 | |
| SCHEMBL20584702 | 0.81 | KLKB1 (0.46) | KLKB1F10 | |
| SCHEMBL20584379 | 0.80 | KLKB1 (0.59) | KLKB1F10 | |
| SCHEMBL22654313 | 0.80 | KLKB1 (0.61) | KLKB1F10 | |
| SCHEMBL20584557 | 0.79 | KLKB1 (0.44) | KLKB1F10 | |
| SCHEMBL20584372 | 0.78 | KLKB1 (0.45) | KLKB1F10 | |
| SCHEMBL20584516 | 0.78 | KLKB1 (0.92) | KLKB1F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180362458-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2018-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180362458-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | KLKB1 1/4885F10 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.